Scientific & Medical Advisors

Prof. Marc-Eric Halatsch is Chief Consultant Neurosurgeon at Cantonal Hospital of Winterthur, Switzerland. Previously, he was Vice-President of the Department of Neurosurgery of the Medical School of Ulm University in Germany and from 2005 to 2009, he was an associate professor of neurosurgery and resident of neurosurgery at Heidelberg University Medical School.

His areas of clinical interest and research are neuro-oncology, including glioblastoma, intraoperative imaging, pediatric neurosurgery, EGF receptor and targeted therapy. He has authored more than 70 scientific papers in international publications and is a member of the Reading Committee of several scientific and medical journals.

Prof. Marc-Eric Halatsch is a medical graduate and doctor of science from the medical school of the University of Göttingen.

Jean-Pierre Bizzari, M.D., is a world-renowned oncology expert. He is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa), member of the International Board of MATWIN (UNICANCER group) and Chairman of the New Drug Advisory Committee of the European Organization of Research and Treatment of Cancer (EORTC).

Previously, Dr. Bizzari was in charge of the clinical development in oncology of several  major international pharmaceutical groups. He notably served as Executive Vice-President, and Director of Clinical Oncology  (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015. He has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Abraxane®, Irinotecan® and also Gliadel® wafer for the treatment of glioblastoma.

Dr. Bizzari has published more than 70 articles in peer-reviewed journals and more than 160 abstracts in scientific congresses, notably on clinical trial methodology and pharmacokinetic/pharmcodynamic studies.

Jean-Pierre Bizzari holds a medical degree specialized in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at the Ontario Cancer Institute, and then the Montreal McGill Cancer Center in Canada.

Dr. Joël Richard, an expert in physico-chemistry and biopharmaceutical R&D, is Head of Technical and Pharmaceutical Operations at MedinCell.

Previously, Joël Richard was Senior Vice President of Peptide Development at Ipsen, in charge of supervising all pharmaceutical development and clinical batch production activities for the pharmaceutical group's peptides and small molecules worldwide. Dr Joël Richard was also Chief Executive Officer of OctreoPharm Sciences GmbH, a subsidiary of the Ipsen group specialising in radiopharmaceuticals for the diagnosis and treatment of cancer. Prior to that, Joël Richard was Director of Pharmaceutical Development of Biological Molecules for the Serono and Merck Serono groups, and also Vice President Research and Director of R&D Europe for Ethypharm.

Dr. Joël Richard has focused his research activities on new formulations and drug delivery systems, such as microspheres, nanoparticles, polymers, chemically modified proteins and supercritical fluid technology, in particular for injectable protein and peptide preparations. He has published 68 peer-reviewed scientific articles, 8 book chapters and is the author of more than 130 international papers and 53 patent families.

Joël Richard is a graduate of the Ecole Normale Supérieure de Cachan (Paris, FR). He obtained his PhD in colloid and interface science at the Pierre and Marie Curie University Paris VI and his Habilitation to Direct Chemistry Research at the University of Bordeaux I.

Dr. Emeline Tabouret is a lecturer and hospital practioner at the Neuro-Oncology Department of Prof. Olivier Chinot at the Timone Hospital (APHM) and a teacher-researcher, holding a Habilitation to Supervise Research, at the Institute of Neurophysiopathology of Marseille, UMR7051, team 8, directed by Prof. Figarella-Branger.
Highly involved in the associative life and learned societies of her field of expertise, Dr. Tabouret is notably a member of the National Council of Universities (CNU) of Oncology - Radiotherapy, of the Brain Tumors group at the European Organization for Research and Treatment of Cancer (EORTC), and of the scientific committee of the Cancéropole PACA. She was also Deputy Secretary General, from 2015 to 2018, and then Secretary General, from 2018 to 2021, of the Association des Neuro-Oncologues d'Expression Françaises (ANOCEF).
Author of more than seventy scientific and medical publications and co-inventor of two families of patents, she has received numerous awards and obtained nearly one million euros of funding for her hospital-academic research work.
In the context of these activities, Emeline Tabouret is particularly interested in the biological role of certain molecules - metalloproteinases - in the development of gliomas and in the resistance to anti-angiogenic therapies.
Dr. Emeline Tabouret holds a degree in medicine and a doctorate in science from the Faculty of Medicine of Marseille.